
Medicine and Health
A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19
C. Chen, L. Yang, et al.
This groundbreaking study conducted by Chih-Jung Chen and colleagues explores the immunogenicity and safety of a novel COVID-19 vaccination strategy that combines ChAdOx1 with MVC-COV1901. Discover how this heterologous prime-boost approach significantly enhances antibody responses, particularly against the Delta variant, without serious adverse events.
Playback language: English
Related Publications
Explore these studies to deepen your understanding of the subject.